Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancers and is clinically defined as lacking expression of the estrogen receptor (ER) and progesterone receptor (PR) and overexpression of the human epidermal growth factor receptor (HER) 2. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.